Skip to main content

Investor RelationsWealth Management:  CA  |  UK  |  AU

Menu

BEIJING | CHINA

Partnering to deliver
global solutions
tailored to your unique needs

Transactions

Our corporate finance solutions are tailored to our clients’ strategic goals and delivered based on in depth expertise across a wide range of sectors globally. We have a strong track record, participating in 80 transactions and raising C$6.1 billion on behalf of our clients in Q1/231.2.

Filter our transactions* using the categories below:

Marathon Gold Corporation
$150m
September 2022

Marathon Gold Corporation

Sole Bookrunner and Co-Lead Underwriter
METALS AND MINING EQUITY CAPITAL MARKETS CANADA
View transaction detail
Akero Therapeutics, Inc.
US$230m
September 2022

Akero Therapeutics, Inc.

Lead Manager (Follow-On)
HEALTHCARE EQUITY CAPITAL MARKETS US
View transaction detail
Aytu BioPharma
US$10m
August 2022

Aytu BioPharma

Joint Bookrunner (Follow-On)
HEALTHCARE EQUITY CAPITAL MARKETS US
View transaction detail
TransMedics Group, Inc.
US$130m
August 2022

TransMedics Group, Inc.

Lead Manager (Follow-On)
HEALTHCARE EQUITY CAPITAL MARKETS US
View transaction detail
Bravo Mining Corp.
C$40.25m
July 2022

Bravo Mining Corp.

Lead-Left and Joint Bookrunner
METALS AND MINING EQUITY CAPITAL MARKETS CANADA
View transaction detail
Oncolytics Biotech
US$65m
June 2022

Oncolytics Biotech

Agent (ATM Offering)
HEALTHCARE EQUITY CAPITAL MARKETS US
View transaction detail
Arcellx, Inc.
US$112m
June 2022

Arcellx, Inc.

Joint Bookrunner (Follow-On)
HEALTHCARE EQUITY CAPITAL MARKETS US
View transaction detail
Cardiol Therapeutics
US$50m
June 2022

Cardiol Therapeutics

Lead Agent (ATM Offering)
HEALTHCARE EQUITY CAPITAL MARKETS CANADA US
View transaction detail
Duke Royalty
£20m
May 2022

Duke Royalty

Joint Bookrunner and Joint Broker (Fundraise)
FINANCIALS CORPORATE BROKING EQUITY CAPITAL MARKETS UK
View transaction detail
HEXO Corp.
US$40m
May 2022

HEXO Corp.

Agent (ATM Offering)
HEALTHCARE EQUITY CAPITAL MARKETS CANADA US
View transaction detail
Zynerba Pharmaceuticals
US$75m
May 2022

Zynerba Pharmaceuticals

Co-Agent (ATM Offering)
HEALTHCARE EQUITY CAPITAL MARKETS US
View transaction detail
Rezolute, Inc.
US$130m
May 2022

Rezolute, Inc.

Co-Manager (Follow-On)
HEALTHCARE EQUITY CAPITAL MARKETS US
View transaction detail
  1. Company information as of June 30, 2022
  2. Transactions valued above C$1.5 million

* Transactions displayed here include transactions of Canaccord Genuity and its predecessors. The logos used in the tombstones represent Canaccord Genuity’s clients unless otherwise specified in the transaction description

How can we help?

If you would like to find out more about Canaccord Genuity or any of our services, please get in touch.